Kristine Yaffe Biography and Net Worth

Director of Alector

Dr. Yaffe has served as a member of our Board of Directors since August 2019. She is the Scola Endowed Chair and the Leon Epstein Chair and Vice Chair, Professor of Psychiatry, Neurology, and Epidemiology, and Director of the Center for Population Brain Health at the University of California, San Francisco (UCSF). Dr. Yaffe is an internationally recognized expert in the epidemiology of dementia and is a foremost leader in identifying modifiable risk factors for dementia that serve as a foundation for prevention. She also currently serves on the Beeson Scientific Advisory Board and the Global Council on Brain Health. Dr. Yaffe previously was the Co-Chair of the United States’ Institute of Medicine’s Committee on Cognitive Aging. Dr. Yaffe has received numerous awards for her groundbreaking contributions to the field, including the American Academy of Neurology’s Potamkin Prize for Alzheimer’s Research in 2017, the NIH Robert S. Gordon, Jr. Award in Epidemiology in 2021, and the Department of Veterans Affairs John B. Barnwell Award for Achievement in Clinical Research in 2022. Dr. Yaffe holds a B.S. in biology-psychology from Yale University and an M.D. from the University of Pennsylvania School of Medicine and has completed residencies in neurology and psychiatry at UCSF. Dr. Yaffe was elected to the National Academy of Medicine in 2019.

What is Kristine Yaffe's net worth?: The estimated net worth of Kristine Yaffe is at least $144.07 thousand as of June 20th, 2025. Dr. Yaffe owns 95,409 shares of Alector stock worth more than $144,068 as of July 28th. This net worth approximation does not reflect any other investments that Dr. Yaffe may own. Learn More about Kristine Yaffe's net worth.
How do I contact Kristine Yaffe?: The corporate mailing address for Dr. Yaffe and other Alector executives is 131 OYSTER POINT BLVD. SUITE 600, SOUTH SAN FRANCISCO CA, 94080. Alector can also be reached via phone at (415) 231-5660 and via email at [email protected]. Learn More on Kristine Yaffe's contact information.
Has Kristine Yaffe been buying or selling shares of Alector?: Kristine Yaffe has not been actively trading shares of Alector during the last quarter. Most recently, Kristine Yaffe sold 1,000 shares of the business's stock in a transaction on Friday, June 20th. The shares were sold at an average price of $1.44, for a transaction totalling $1,440.00. Following the completion of the sale, the director now directly owns 95,409 shares of the company's stock, valued at $137,388.96. Learn More on Kristine Yaffe's trading history.
Who are Alector's active insiders?: Alector's insider roster includes Robert King (Insider), Robert Paul (Insider), Arnon Rosenthal (CEO), Richard Scheller (Director), Shehnaaz Suliman (COO), Kristine Yaffe (Director), and Calvin Yu (VP). Learn More on Alector's active insiders.
Are insiders buying or selling shares of Alector?: During the last year, insiders at the sold shares 14 times. They sold a total of 338,673 shares worth more than $513,284.20. The most recent insider tranaction occured on June, 3rd when insider Grace Wong-Sarad sold 3,475 shares worth more than $6,533.00. Insiders at Alector own 8.3% of the company. Learn More about insider trades at Alector.
Information on this page was last updated on 6/3/2026.

Kristine Yaffe Insider Trading History at Alector

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
6/20/2025	Sell	1,000	$1.44	$1,440.00	95,409

Kristine Yaffe Buying and Selling Activity at Alector

Alector Company Overview

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.50

$1.50

$1.53

50 Day Range

MA: $1.79

$1.39

$2.21

2 Week Range

Now: $1.50

$1.09

$3.40

Volume

36,917 shs

Average Volume

779,826 shs

Market Capitalization

$165.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.6